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ABSTRACT
Major advances have been made regarding the utilization of artificial intelligence in health
care. In particular, deep learning approaches have been successfully applied for automated
and assisted disease diagnosis and prognosis based on complex and high-dimensional data.
However, despite all justified enthusiasm, overoptimistic assessments of predictive perfor-
mance are still common. Automated medical testing devices based on machine-learned pre-
diction models should thus undergo a throughout evaluation before being implemented into
clinical practice. In this work, we propose a multiple testing framework for (comparative)
phase III diagnostic accuracy studies with sensitivity and specificity as co-primary end-
points. Our approach challenges the frequent recommendation to strictly separate model
selection and evaluation, i.e. to only assess a single diagnostic model in the evaluation study.
We show that our parametric simultaneous test procedure asymptotically allows strong con-
trol of the family-wise error rate. Moreover, we demonstrate in extensive simulation stud-
ies that our multiple testing strategy on average leads to a better final diagnostic model and
increased statistical power. To plan such studies, we propose a Bayesian approach to deter-
mine the optimal number of models to evaluate. For this purpose, our algorithm optimizes
the expected final model performance given previous (hold-out) data from the model devel-
opment phase. We conclude that an assessment of multiple promising diagnostic models
in the same evaluation study has several advantages when suitable adjustments for multiple
comparisons are conducted.
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1 Introduction
Research projects concerned with the application of machine learning (ML) techniques for disease diagnosis
and prognosis have steadily grown in number over the last years. This is indicated, among others, by several
review and overview publications (Ching et al., 2018; Jiang et al., 2017; Litjens et al., 2017; Miotto, Wang,
Wang, Jiang, & Dudley, 2017). In particular, the capabilities of end-to-end deep learning approaches on
such supervised learning tasks are highly promising. For instance, vast advances have been reported in the
literature regarding cancer diagnosis with deep neural networks (Hu et al., 2018). End-to-end deep learning
refers to a trend involving deep (neural network) model architectures which are able to learn highly complex
relationships between predictors and the target variable while having less parameters than traditional (more
shallow) models with comparable performance (Goodfellow, Bengio, & Courville, 2016). In the training
process, highly complex features are derived automatically by the learning algorithm (LeCun, Bengio, &
Hinton, 2015). This framework contrasts the traditional pipeline of domain specific data preprocessing
and hand-crafted features in combination with simpler prediction models. Despite all the recent success of
machine learning, there are still challenges regarding over-optimistic conclusions drawn from finite datasets
which may to a large extend be attributed to the following two (broad) categories:
1. Study design and reporting: The most popular recommendation to split data for training, selection
and evaluation is frequently employed in practice (Friedman, Hastie, & Tibshirani, 2009; Géron,
2017; Goodfellow et al., 2016; Japkowicz & Shah, 2011; Kuhn & Johnson, 2013; Zheng, 2015). In
the ML community, the according datasets are commonly denoted as training, validation and test set.
However, the less of the defining properties of the study (e.g. data source, data splitting modalities,
performance measure, comparator, etc.) are specified in advance, the more ’opportunities’ present
themselves to the researchers to influence the results to match their expectations (Boulesteix, 2009;
Boulesteix, Lauer, & Eugster, 2013; Boulesteix & Strobl, 2009; Jelizarow, Guillemot, Tenenhaus,
Strimmer, & Boulesteix, 2010). For diagnostic accuracy studies, several design-related sources of
bias have been identified in the literature (Lijmer et al., 1999; Rutjes et al., 2006; Schmidt & Factor,
2013; P. Whiting et al., 2004; P. F. Whiting et al., 2011). According to Rutjes et al. (2006), relevant
sources for overoptimistic conclusions are selection of non-consecutive patients, analysis of retro-
spective data and focus on severe cases and healthy controls. Another issue is an in-transparent
communication (conscious or not) of the results (Bossuyt et al., 2015; Collins, Reitsma, Altman, &
Moons, 2015; Ochodo et al., 2013). This may prevent other research teams to replicate the findings
on similar problems (replicability) or even on the same data (reproducibility) (Jasny, Chin, Chong,
& Vignieri, 2011; Peng, 2011).
2. Sampling variability: True predictive performance of a diagnostic model is not known but only
estimated based on data. Even in the ideal case in which the evaluation data is independent of
the data used for model development and all modalities of the evaluation study are specified in
advance in a study protocol, the empirical performance is still a random variable and may realize
at a high value just due to chance. From our perspective, this fact is often times overlooked within
the machine learning community.
This work is primarily concerned with the quantification of sampling variability. Our primary statistical
inference goal is to bound the probability for false positive claims regarding the performance of a prediction
model, i.e. the type I error rate. On the other hand, we of course seek to identify a truly good model with
high probability. It may be argued that methodological research in machine learning or bioinformatics does
not (need to) have the goal to control the type I error rate. We agree with this view in the context of the
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early development of new algorithms and prediction models and acknowledge that exploratory research is
of utmost importance for the scientific process. In machine learning applications, this amounts to trying out
a wide variety of learning algorithms deemed suitable for the prediction task at hand. This makes sense, as
by the no-free-lunch theorem of statistical learning, no single algorithm gives universally best results for all
prediction tasks (Shalev-Shwartz & Ben-David, 2014). Modern algorithms additionally involve the tuning
of several hyperparameters. The performance of (deep) neural networks depends for example on depth
(number of layers), width (neurons per layer), activation function(s) and further hyperparameters related
to regularization (e.g. dropout rate) and optimization (e.g. loss function, learning rate, mini batch size)
(Bengio, 2012). In effect, usually dozens, hundreds or even thousands of candidate models are initially
trained and compared.
However, at some point a reliable statement regarding the model performance is required. This is in par-
ticular the case in medical applications where the consequences of a wrong decision could ultimately be
life-threatening, for instance when a new (automated) diagnostic tool is implemented into clinical practice.
Additionally, depending on the regulatory context, a throughout evaluation study might even be mandatory.
Pesapane, Volonté, Codari, and Sardanelli (2018) give an overview over the current regulatory framework
for artificial intelligence empowered medical devices in the EU and the US from the viewpoint of radiology.
They also comment on future developments, in particular the new Medical Devices Regulation (MDR) and
the new In Vitro Diagnostic Medical Device Regulation (IVDR) in the EU (European Parliament, Council
of the European Union, 2017a, 2017b). These new regulations will certainly be relevant for the application
of machine learning methods for medical testing purposes and will apply from May 2020 and May 2022,
respectively.
Throughout investigations of devices for automated medical testing purposes are still rather scarce (as are
such devices themselves). A recent positive example covers the IDx-DR device which allows diagnosis of
diabetic retinopathy in diabetic patients via deep learning based on retinal color images (Abràmoff et al.,
2016). Diagnostic accuracy was assessed in an extensive observational clinical trial involving 900 patients,
which lead to a marketing permit by the FDA2. In this study, only a single model was (successfully) evalu-
ated on the final dataset. This default strategy is often advised in machine learning and diagnostic accuracy
research and is reasonable if previously available data for model training and selection is (a) large in number
and (b) representative of the intended target population. However, when potentially hundreds of modeling
approaches are compared on (quantitatively and/or qualitatively) modest datasets, the model selection pro-
cess can rarely be concluded with confidence. While the default approach enables an unbiased estimation
and simple statistical inference, one is thus bound to this one-time model choice under uncertainty. In effect,
this strategy is quite inflexible as it is impossible to retrospectively correct a flawed model selection without
compromising the statistical inference in the evaluation study.
To address this issue, Westphal and Brannath (2019a, 2019b) recently adapted a multiple testing approach
from Hothorn, Bretz, and Westfall (2008) to explicitly take into account that multiple models are assessed
simultaneously on the same evaluation dataset. In effect, model selection can be improved with help of the
test data (Westphal & Brannath, 2019b). The employed simultaneous test procedure is based on the (approx-
imate) multivariate normal distribution of performance estimates. An advantage of this procedure is that
the multiplicity adjustment needs to be less strict when candidate models give (highly) similar predictions.
This approach allows approximate control of the overall type I error rate and construction of simultaneous
confidence regions as well as corrected (median-conservative) point estimates. Moreover, it was found that
selecting multiple promising models can increase statistical power for the evaluation study compared to the
default approach where only the best (cross-)validation model is evaluated. The main goal of this work is
2https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN180001.pdf (last accessed November 11, 2019)
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to extend this existing framework to diagnostic accuracy trials with co-primary endpoints sensitivity and
specificity.
In this context, a concise connection to the taxonomy of diagnostic research seems appropriate. Among the
many resources available regarding this topic, terminology varies quite substantially (Knottnerus & Buntinx,
2009; Pepe, 2003; Pepe, Feng, Janes, Bossuyt, & Potter, 2008; Zhou, McClish, & Obuchowski, 2009). We
will adhere to Knottnerus and Buntinx (2009, chapter 2), who established a system of five study phases in
diagnostic research. Our work is mainly tailored towards cross-sectional phase III (comparative) diagnostic
test accuracy (DTA) studies which ask the question:
"Among patients in whom it is clinically sensible to suspect the target disorder, does the
level of the test result distinguish those with and without the target disorder?"
(Knottnerus & Buntinx, 2009)
The goal of a such studies is generally to provide evidence that a new index (or candidate) diagnostic
test outperforms either a given comparator or, if no such competing test is available, a given performance
threshold. Performance, i.e. sensitivity and specificity, is measured with regard to the (defined) ground truth
which is in the optimal case derived by a so-called gold standard. It may however be infeasible to implement
such a gold standard in the DTA study or there may not even exist one. Thus, typically a reference standard
is defined as the best available approximation of the gold standard. Common reasons to install an index test
in clinical practice are either lower invasiveness or costs. This balances the fact that, by definition, the index
test can not have better performance than the reference test. This is relevant for predictive modeling as, from
the model evaluation perspective, a machine-learned prediction model is nothing more than a (potentially
very complex) diagnostic test - at least when embedded in a medical device used for automated or assisted
disease diagnosis. We refer to Knottnerus and Buntinx (2009, chapters 1-3) for a general introduction
in diagnostic research and a throughout treatment of DTA studies. Study design and reporting issues are
discussed by Ochodo et al. (2013), Collins et al. (2015) and Bossuyt et al. (2015).
Multiple testing methodology is not particularly popular, neither for medical test evaluation nor in machine
learning (Westphal & Brannath, 2019b). As indicated above, the recommendation to evaluate a single
final model or test on independent data has prevailed in both domains. In this case, no adjustments for
multiplicity are necessary as the final model is selected independently of (i.e. prior to) the evaluation
study. Our approach has some overlap to so-called benchmark experiments in predictive modeling. Among
others, Hothorn, Leisch, Zeileis, and Hornik (2005) and Demšar (2006) showcase different approaches for
the comparison of learning algorithms over multiple (real or artificial) datasets and inference regarding their
expected performances. In contrast, we aim to evaluate prediction models (conditional on the learning data),
which is arguably more important at the end of the model building process - right before implementation of
a specific model in (clinical) practice. In medical testing applications, it is natural to consider only a single
index (candidate) test. This is particularly the case, when different tests are based on separate biological
samples. It would then often not be considered ethically justifiable to assess more than a single index test
and the reference test on the same patients. In contrast, when all index test are derived from the same data
sample, e.g. retinal images, the number of index tests (diagnostic models) should be primarily guided by
statistical considerations as long as the type I error rate can be controlled.
The primary goal of this work is to provide a multiple testing framework for the assessment of sensitivity
and specificity as co-primary endpoints for multiple diagnostic procedures (prediction models) on the same
data. To our knowledge, such an approach has not been proposed in the literature so far. In section 2, we
introduce core assumptions and notation and establish our inference framework. In section 3, we describe
a novel Bayesian approach to determine the optimal number of models to include in the final evaluation
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study based on preliminary data. In section 4, we show results of several numerical experiments: Our main
goals are (a) an assessment of finite sample properties regarding (e.g.) control of the type I error rate and (b)
a comparison of different approaches for model selection prior to the evaluation study. Finally, in section
5, we summarize our findings, point out limitations of our framework and give an outlook on possible
extensions.
2 Statistical model
2.1 Prerequisites
We consider predicting a binary label Y ∈ {0, 1} based on P ∈ N features X ∈ RP . Our canonical
example in this work will be the distinction between diseased (having a given target condition, Y = 1) and
healthy (Y = 0) subjects. In medical applications, the target Y should be obtained by the (best available)
reference standard and forms the ground truth for learning and evaluation. The goal of supervised machine
learning is to provide a prediction model fˆ : x 7→ yˆ with high performance. In practice, this is achieved
by a learning algorithm A (e.g. stochastic gradient descent) which outputs a prediction model fˆ (e.g. a
neural network) based on learning data L = {(xi, yi)}nLi=1. We write fˆ = A(L) for short. We emphasize
that we are concerned with the assessment of a specific model fˆ trained on specific data L and not with
the properties of the algorithm A that was used to learn fˆ . Finally, we note that, from the viewpoint of
predictive modeling, disease diagnosis and prognosis essentially only differ regarding the time lag between
capturing the features x and the label y - at least if this lag is approximately equal in the population of
interest. Otherwise, a time to event analysis may be more appropriate. For the sake of brevity, we will
focus on diagnosis tasks in the following. In medical diagnosis, sensitivity (Se) and specificity are (Sp) are
often both assessed simultaneously. We thus consider the tuple θ = (Se,Sp) as the performance measure
of interest where
Se = P(fˆ(X) = 1|Y = 1) and Sp = P(fˆ(X) = 0|Y = 0). (1)
This is advantageous compared to just considering the overall accuracy Acc = P(fˆ(X) = Y ) = % Se +(1−
%) Sp in the sense that neither the accuracy in healthy or diseased alone dominates our perception of the
predictive performance if the disease prevalence % = P(Y = 1) is small.
As we have outlined in section 1, it is usually recommended to conduct a final performance assessment
on independent evaluation or test data E = {(xi, yi)}nEi=1. Performance estimates on the learning data are
generally a bad indicator of the true performance, in particular when a highly complex model might have
overfitted the learning data. We assume that E is an i.i.d. sample from the unknown joint distribution
D(X,Y ) of X and Y . Moreover, we assume that M ∈ N models fˆm = Am(L), m ∈ M = {1, . . . ,M},
have been initially trained in the learning phase via different learning algorithms Am. A subset S ⊂ M
of these initial candidate models is selected for evaluation. To simplify the notation we assume that the
candidate models are ordered such that S = {1, . . . , S} with 1 ≤ S ≤M . Different approaches to identify
S are discussed in section 3.1. This is implemented in practice by training models first only on the so-called
training data T ⊂ L, a subset of the learning data. The remaining validation data V = L \ V is than used
for a performance assessment of the resulting preliminary models fˆ−m = Am(T ). The model(s) selected
for evaluation are than re-trained with all available data L = T ∪ V before going into the evaluation study
with the expectation that this (slightly) increases their performance. This procedure is know as (simple)
hold-out validation. There exist several variations and alternative strategies such as cross-validation or
bootstrapping (Goodfellow et al., 2016; Kuhn & Johnson, 2013). They can stabilize model selection, are
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however computationally more expensive as models have to be re-trained several times which is not always
feasible in practice. For simplicity, we will focus on simple hold-out validation in this work.
Note that by performance, we refer to the true population performance θ = (Se,Sp) of a model fˆ as
defined in (1) for sensitivity and specificity. Validation performance (sensitivity, specificity) is referring
to the empirical performance (sensitivity, specificity) of the preliminary model fˆ− (trained only on T )
estimated on the validation data and denoted by θˆ(V) = (Ŝe(V), Ŝp(V)), in slight abuse of notation. In
contrast, evaluation or test performance is referring to the empirical performance of the final model fˆ (re-
trained on L). It is estimated on the final evaluation or test dataset E and denoted as θˆ = (Ŝe, Ŝp). We
will often deal with several models fˆm, m ∈ M, and will usually refer to a specific model fˆm just by the
corresponding index m.
2.2 Study goal
Our overall goal is to identify a diagnostic or prognostic prediction model with high sensitivity and speci-
ficity from the M initially trained models. Additionally, we aim to show superiority of at least one model
compared to prespecified thresholds θ0 = (Se0,Sp0) ∈ (0, 1)2. Alternatively, θ0 = θ(fˆ0) is the unknown
performance of a comparator fˆ0, i.e. an established diagnostic testing procedure which is also estimated
in the evaluation study. In the following, we will focus on the former scenario which is also simpler to
implement in our numerical experiments in section 4. Throughout this work, we assume that the evaluation
study is declared as successful if and only if superiority in both endpoints for at least one candidate model
m ∈ S relative to the the comparator θ0 can be demonstrated. This so-called co-primary endpoint analysis
is the standard approach in confirmatory diagnostic accuracy studies (Committee for Medicinal Products
for Human Use, 2009). Vach, Gerke, and Høilund-Carlsen (2012) discuss other approaches in detail. The
system of null hypotheses is thus given by
HS = {Hm : HSem ∪HSpm , m ∈ S} (2)
where HSem : Sem ≤ Se0 and HSpm : Spm ≤ Sp0 .
Equivalently, the hypothesis system can be expressed as
HS = {Hm : ϑm = min(Sem,Spm +∆0) ≤ ϑ0, m ∈ S}.
Hereby, ∆0 = Se0−Sp0 ∈ (−1, 1) specifies to which extent we prioritize sensitivity over specificity (or
vice versa). For simplicity, we only consider ∆0 = 0 in the numerical experiments in this work. The goal
of the evaluation study is to estimate the unknown sensitivities and specificities, provide confidence bounds
for these estimates and obtain a multiple test decision for the hypothesis system (2).
A multiple test ϕ = (ϕ1, . . . , ϕS) depends on the evaluation data E and results in a binary vector ϕ ∈
{0, 1}S of test decisions whereby Hm is rejected if and only if ϕm = 1. In a regulatory setting, it is usually
required that ϕ shall control the family-wise error rate (FWER) strongly at significance level α, i.e. we
require for all possible parameter configurations θ
FWERθ(ϕ) = Pθ
( ⋃
m∈S0
{ϕm = 1}
)
≤ α. (3)
Hereby, S0 = S0(θ, θ0) ⊂ S is the index set of true null hypothesis, i.e. we have either Sem ≤ Se0 or
Spm ≤ Sp0 for all m ∈ S0. Any parameter θ for which FWERθ(ϕ) becomes maximal is called a least
favorable parameter configuration (LFC). In this work, we will restrict our attention to asymptotic control of
6
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the FWER, i.e. (3) shall only hold as n = nE →∞. We will investigate the finite sample FWER in realistic
and least-favorable settings in section 4. As described by Westphal and Brannath (2019a), we extend ϕ to
a multiple test for the actually relevant hypothesis system
H = HM = {Hm : ϑm ≤ ϑ0, m ∈M} (4)
concerning all initial candidate models fˆm, m ∈ M, by setting ϕm = 0 for all m ∈ M \ S. That is
to say, a model m cannot be positively evaluated (ϕm = 1) when it is not selected for evaluation. This
natural definition has two consequences. Firstly, the extended test retains (asymptotic) FWER control as
only non-rejections are added. Secondly, we can compare different model selection strategies because the
extended multiple test always operates onH = HM and not only onHS (Westphal & Brannath, 2019a).
2.3 Parameter estimation
We assume that a subset of promising models S = {1, . . . , S} ⊂ M has been selected prior to the evaluation
study. Suitable strategies for that matter are presented in section 3.1. The observed feature-label data
E = {(xi, yi)}ni=1 from the evaluation study is transformed to the actual relevant binary similarity matrices
QSe ∈ {0, 1}n1×S and QSp ∈ {0, 1}n0×S for the diseased (y = 1) and healthy (y = 0) subpopulation,
respectively. Hereby, n1 and n0 are the number of diseased and healthy subjects of the n = nE = n1 + n0
evaluation study subjects. The entry ofQ in row i and column m is equal to one if the prediction of the i-th
observation by the m-th model is correct and zero if it is wrong. The sample averages
Ŝe =
1
n1
n∑
i=1
1(fˆ(xi) = yi = 1) and Ŝp =
1
n0
n∑
i=1
1(fˆ(xi) = yi = 0).
can thus be calculated as the column means of these similarity matrices (Westphal & Brannath, 2019a,
2019b). Moreover, we can estimate the covariances ΣSe = cov(Ŝe) and ΣSp = cov(Ŝp) as the sample
covariance matrices of the similarity matrices divided by factors of n1 and n0, respectively.
A problem arises when a sample proportion of one (or zero) is observed. This is not unlikely to happen in the
realistic scenario that either sensitivity or specificity of several models are close to one and the evaluation
sample size is not large. In this case, say if Ŝem = 1, the plug-in variance estimate Ŝem(1 − Ŝem)/n1
collapses to zero. In effect, ΣˆSe becomes singular and the statistical test procedure introduced in the next
section is no longer directly applicable. Different approaches to deal with this problem have been described
in the univariate context (Bolstad & Curran, 2016; Jung, 2017). A popular approach is to employ the
posterior mean of a Bayesian Beta-binomial model as a point estimator of the unknown mean. When taking
a uniform, i.e. Beta(1, 1), prior, this results in the point estimate (u+ 1)/(n+ 2) where u is the observed
number of successes, compare Bolstad and Curran (2016, Chapter 9). Simply speaking, this amounts
to adding two pseudo-observation - one correct and one wrong prediction. As a consequence, estimated
proportions are shrunk (slightly) towards 0.5.
This idea can be transferred to the multivariate case (S > 1) which is more complex as the correlation
between empirical performances comes into play. Westphal (2019) recently derived a multivariate Beta-
binomial model which can be employed for that matter. Besides marginal prior distributions, it also involves
a prior on second-order moments, and thus the correlation structure. A vague, conservative prior can be
specified as S independent uniform distributions. Marginally, this again amounts to adding two pseudo
observations (one correct and one false prediction) per model. Moreover, for each model pair half of the
added correct pseudo-prediction is counted as common. We can then use the posterior mean and covariance
as estimates Ŝe and Σ̂Se = ĉov(Ŝe) and independently apply the same approach for Ŝp and Σ̂Sp. For
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finite sample sizes, the influence of this adaptation is conservative as mean estimates are shrunk towards
0.5. Variance estimates are slightly inflated. In particular, all variances are guaranteed to be strictly greater
than zero which solves the initially mentioned problem. Moreover, the correlation matrix is slightly shrunk
towards the identity matrix. We have employed these regularized estimators in all numerical experiments
in section 4. Note that they are asymptotically equivalent to their naive counterparts and the asymptotic
properties described in the next section thus remain unchanged. A detailed description can be found in
appendix A.1.
2.4 Statistical inference
Our goal is to apply the so-called maxT-approach to hypothesis system (2) (Hothorn et al., 2008). This
simultaneous test procedure has previously been utilized for the assessment of the overall classification
accuracy of several binary classifiers (Westphal & Brannath, 2019a, 2019b). This multiple test enables us
to reduce the need for multiplicity adjustment in case several similar models are evaluated. Similarity is
measured by the correlation of (empirical) performances which depends on the probability of a common
correct prediction in our context (Westphal & Brannath, 2019a). The maxT-approach relies on determining
a common critical value cα, which depends on the empirical correlation structure, such that each hypothesis
Hm is rejected if and only if
Tm = min(T
Se
m , T
Sp
m ) > cα.
The test statistics are defined in a standard manner via
T Sem =
Ŝem − Se0
ŝe(Ŝem)
(5)
whereby ŝe(Ŝem) =
√
Ŝem(1− Ŝem)/n1 is the estimated standard error of Ŝem. The test statistics T Spm are
defined accordingly. When only a single model is evaluated with regard to co-primary endpoints the tests
regarding sensitivity and specificity each need to be conducted at local level α. This is because the least
favorable parameter configuration (LFC) is of the form
Se = Se0 ∧Sp = 1 or Se = 1 ∧ Sp = Sp0, (6)
i.e. one parameter (Se or Sp) is equal to one and the other parameter lies on the boundary of the null hy-
pothesis. Similarly, for our case of S candidate models, the two cases described in (6) are possible for each
dimension m ∈ S = {1, . . . , S}, resulting in 2S potential LFCs. We could attempt to identify the single
least favorable configuration in terms of multiple testing adjustment which depends on the resulting true
correlation matrix. However, the computational burden of this extensive approach increases exponentially
in S as 2S critical values would have to be computed.
We will instead focus on a more direct approach. Assume we knew if ∆Sem = Sem−Se0 < Spm−Sp0 =
∆Spm or if ∆Sem > ∆
Sp
m is true for each m ∈ S . For simplicity, we assume that ∆Sem and ∆Spm are not exactly
equal in the following. Define the indicator variables bm = 1(∆Sem < ∆
Sp
m ), b = (b1, . . . , bS) and the
corresponding diagonal matrixB = diag(b). Moreover, we define
B2 =
(
B
IS −B
)
∈ {0, 1}2S×S and T2 =
(
T Se
T Sp
)
∈ R2S×1
whereby IS is the S-dimensional identity matrix. Finally, we can define the S-dimensional vector of test
statistics
T b = (B2)
>T2 ∈ RS . (7)
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Our goal is to use this test statistic to obtain a multiple test for the hypotheses system (2) which can, due to
the definition of the variables bm, be rewritten as
HS = {Hm : bm∆Sem + (1− bm)∆Spm ≤ 0, m ∈ S}. (8)
The LFC for (8) is specified by Seb = bSe0 +(1S − b) and Spb = b + (1S − b) Sp0. That is to say, for
each m ∈ S, Sem is projected to Se0 and Spm is projected to one in the case bm = 1 and vice versa when
bm = 0. Then, assuming n1/n→ % 6= 0 as n = n1 + n0 →∞, under the LFC θb = (Seb,Spb), we have
T b(n)
D−→ NS(0,Rb), n→∞. (9)
Hereby, the correlation matrix Rb is defined as BRSeB + (IS −B)RSp(IS −B). This result is proven
in appendix A.2.
The vector b and thus the matrices B and B2 are of course unknown in practice which makes the fol-
lowing two adjustments necessary. Firstly, we will replace T b with the vector T with entries Tm =
min(T Sem , T
Sp
m ) ≤ T bm. Secondly, we need to estimate the correlation matrix Rb, in order to compute a
critical value cα. An obvious candidate is
Rˆb = BˆRˆSeBˆ + (IS − Bˆ)RˆSp(IS − Bˆ) (10)
with Bˆ = diag(bˆ) and bˆm = 1(Ŝem − Se0 < Ŝpm − Sp0) and RˆSe and RˆSp derived from the empirical
covariances, compare section 2.3. As all components in (10) are consistent estimators of their corresponding
population quantities, Rˆb is a consistent estimator of Rb by virtue of the continuous mapping theorem,
compare appendix A.2. To define a multiple test, we calculate a common critical value cα such that
P(max
m∈S
(T bm) ≤ cα) ≈ ΦS(cα, Rˆb) =
∫ cα
−∞
. . .
∫ cα
−∞
φS(x, Rˆ
b)dx = 1− α, (11)
under the ’estimated LFC’ θbˆ. Hereby φS and ΦS denote the density and distribution function of the S-
dimensional standard normal distribution with mean 0 and covariance matrix Rˆb. In practice, cα can be
found by numerical integration, e.g. with help of the R package mvtnorm (Genz et al., 2019).
Altogether, we have (a) asymptotic multivariate normality of T b, compare (9), (b) a consistent estimate
Rˆb of the correlation matrix via (10) and (c) T ≤ T b (deterministically). Following the argumentation of
Hothorn et al. (2008), this allows to define a multiple test ϕ via ϕm = 1 ⇔ Tm > cα such that the FWER
is asymptotically controlled at level α. We can also construct (e.g.) one-sided simultaneous confidence
regions for Se and Sp via
CISe1−α,m =
(
Ŝem − cα · ŝe(Ŝem), 1
)
and CISp1−α,m =
(
Ŝpm − cα · ŝe(Ŝpm), 1
)
.
Note, that the coverage probability Pθ(Se ∈ CISe1−α ∧Sp ∈ CISp1−α) may be smaller than 1 − α. Instead,
due to the duality between confidence interval and test decision, we have asymptotically
Pθ
( ⋃
m∈S
{
Sem /∈ CISe1−α,m ∧ Spm /∈ CISp1−α,m
})
≤ α.
When setting α = 0.5, the lower confidence bounds can be used as a corrected point estimators S˜e, S˜p with
the property that the overall probability that both S˜em and S˜pm overestimate their target for any m ∈ S is
asymptotically bounded by 50%, compare Westphal and Brannath (2019a).
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3 Practical aspects
3.1 Study planning
A prominent recommendation in machine learning and in medical testing is to strictly separate model devel-
opment (training and selection) and model evaluation (performance assessment), compare section 1. The
most straightforward implementation of this strategy is to select a single final model prior to the evaluation
study. Often times this is done by choosing the model with the highest empirical performance on a (hold-
out) validation dataset out of the M initially trained models, as described in section 2.1. When evaluating
binary classifiers regarding their overall accuracy, previous work has shown that it is beneficial to evaluate
multiple promising models simultaneously, e.g. all models within one standard error of the best validation
model. Westphal and Brannath (2019a, 2019b) found that this so-called within 1 SE selection rule leads
to evaluation studies with higher power. Additionally, it allows to select the final model based on empir-
ical test performances which in turn increases the final model performance. On the downside, the point
estimate for the final model performance is upward biased which can however be corrected with help of a
median-conservative estimator. To obtain multiplicity adjusted test decisions and corrected point estimates,
Westphal and Brannath (2019a, 2019b) applied the so-called maxT-approach based on work by Hothorn et
al. (2008) which we adopted to the co-primary endpoint setting in section 2.4 of this work.
To arrive at a suitable selection of prediction models for the evaluation study, more work is necessary when
sensitivity and specificity are assessed simultaneously. We might still use the standard within 1 SE (Acc) rule,
but its success can be expected to depend on the disease prevalence % = P(Y = 1). A simple adaptation
is the within 1 SE (bAcc) rule based on the balanced accuracy bAcc = (Se + Sp)/2 instead of the overall
accuracy Acc. While the within 1 SE approach is intuitive and has proven to work empirically, it lacks a
throughout theoretical justification. In particular, the question which multiplier k ≥ 0 results in the best
within k SE rule remains open.
In the following, we introduce a more elaborate algorithm for model selection which aims to derive the
models to be evaluated in an optimal fashion. We are dealing with a subset selection problem, that is to
say that our goal is to find the best subset S ⊂ M, whereby ’best’ is yet to be defined. This topic has
been extensively studied in the literature, see e.g. Liese and Miescke (2008, chapter 9), for a throughout
treatment from the viewpoint of Bayesian decision theory. From this perspective, the usual approach is to
pick the decision (here: the subset S) from an appropriate decision space (here: {0, 1}M ) which minimizes
the posterior expected loss, or equivalently maximizes the posterior expected utility. Liese and Miescke
(2008, p. 548), give several examples for appropriate loss functions for the subset selection problem. For
instance, we may define the utility of picking subset S ⊂ M given the true parameter θ = (Se,Sp) and
ϑ = min(Se,Sp + ∆0) (understood component-wise) as
Uθ(S) = max
m∈S
ϑm − max
m∈M
ϑm − c|S|. (12)
In (12), we balance out the best selected model performance maxm∈S ϑm versus the subset size S = |S|.
Note that, the second term in (12) is independent of S. This trade-off is necessary as we could easily
maximize maxm∈S ϑm by just selecting all models S =M. The parameter c thus has to be set by the user
to guide this trade-off. This is also the case for most other popular utility functions proposed in the literature
(Liese & Miescke, 2008). This will be problematic in practice, because there is (again) no clear-cut solution
how to specify the ’hyperparameter’ c.
To overcome this issue, we will use a utility function which has no hyperparameter in the above sense to
specify. For this, it is important to realize that we are really dealing with a two-stage selection problem.
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First, our goal is to select a suitable subset S ⊂ M of models before the evaluation study. Secondly, from
S we aim to select a final model m∗ ∈ S with help of the evaluation study for implementation in practice.
As our ultimate goal is to obtain a model or medical test with high performance, i.e. high sensitivity and
specificity, we propose to optimize the expected final model performance
EFP(S) = EFPθ(S) = Ep(θˆ |θ)ϑm∗ =
∑
m∈S
ϑmPp(θˆ |θ)(m
∗ = m) (13)
=
∑
m∈S
min(Sem,Spm +∆0)Pp(θˆ |θ)(m
∗ = m)
depending on the subset of models S ⊂M selected for evaluation. The final model m∗ = m∗(θˆ) is chosen
based on the empirical performances in the evaluation study and thus a random variable, unlike the fixed pa-
rameter θ = (Se,Sp). Our default final model choice will be m∗ = argmaxm∈S min(T Sem , T
Sp
m ), compare
section 3.2. The expectation in (13) is taken with respect to p(θˆ |θ), the distribution of θˆ in the evaluation
study with n observations which depends on θ. Assuming the prediction models are deterministic, p is a
deterministic transformation ofDn(X,Y ), the distribution of the feature-label data (X, Y ) as described in the
beginning of section 2.3. Of course, both distributions are unknown in practice, because θ is not known.
In formulation (13), EFP depends on S ⊂ M for which in principle there are 2M choices. For the sake of
simplicity we omit the choice S = ∅ in this work which corresponds to not conduct any evaluation study at
all. In reality, this choice could of course be sensible, for instance if the empirical performances observed on
the validation data suggest that none of the models satisfies our requirements θ0 = (Se0,Sp0). In order to
simplify the decision problem which models to evaluate and its numerical optimization, we rank our models
before choosing S which leaves us with only M choices instead of 2M , namely S = {1}, S = {1, 2}, . . . or
S =M. Consequently, we may write EFP(S) instead of EFP(S) after ranking the models. How to rank
models is not as obvious as in the single endpoint case concerned with the overall classification accuracy.
Our default choice will be a ranking according to min(T Sem (V), T Spm (V)), whereby the test statistics are
defined as in (5) but based on the validation data. In other words, the models are ranked according to the
validation evidence that Hm is false.
The main idea behind our novel optimal EFP selection rule is to maximize an estimate ÊFP(S) of EFP(S)
before the evaluation study. Taking the viewpoint of Bayesian decision theory, we aim to maximize the
posterior expected utility
ÊFP(S, pi(θ | V)) = Epi(θ | V) EFPθ(S) = Epi(θ | V)Ep(θˆ |θ)ϑm∗ (14)
at the time point of decision making, right before the evaluation study. The expectation is taken with regard
to the posterior distribution pi = pi(θ | V) of θ given the validation data V . More concretely, we assume
that pi = (piSe, piSp) is composed of two multivariate Beta distributions, Se ∼ piSe and Sp ∼ piSp. For that
matter, we utilize a recently proposed multivariate Beta (mBeta) distribution allowing arbitrary dependency
structures between different Beta variables (Westphal, 2019). As an initial prior distribution pi(θ) of θ, we
use a vague (uniform) prior by default. A potential alternative would be to specify an informative prior
distribution e.g. according to previous experimental data (Westphal, 2019).
This approach allows us to sample θ = (Se,Sp) from pi and subsequently to sample estimates θˆ =
(Ŝe, Ŝp) from p = p(θˆ |θ). In our case, the sampling distribution p of θˆ is a multivariate Binomial distri-
bution with mean vector θ and correlation structure Cθˆ. The correlation structure is also sampled from pi
in terms of corresponding mixed second-order moments. Utilizing this Bayesian model allows us to fore-
cast both, true parameter values and their respective estimates including the dependency structure of both.
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This enables a simulation of the selection process in the evaluation study and the inherent selection-induced
bias problem. In our numerical implementation, we iteratively repeat this process until our computational
budget has been exhausted and finally average the results to approximate the (double) expectation in (14)
for all S. Hereby, we specify a maximal number of models Smax for evaluation in advance to reduce the
computational burden of the optimization. A solution to the subset selection problem in dependence of the
validation data V is then simply S = {1, . . . , S∗} with
S∗ = S∗(V) = argmax1≤S≤Smax ÊFP(S, pi(θ | V)). (15)
Given the assumed prior distribution, the initial model ranking, the statistical modeling assumptions (con-
cerning pi and p) and the numerical approximations, the procedure results in an approximate Bayes action
as we approximately maximize the posterior expected utility EFP(S). The numerical implementation of
the optimal EFP selection rule is described in more detail in appendix B.
Figure 1 illustrates the trade-of between selecting too few and too many models for evaluation. The curves
represent ÊFP(S) simulated by the above sketched algorithm for exemplary validation performance esti-
mates θˆ(V) based on a specific data example with nV = 100 from our simulation database. The three
different curves correspond to different evaluation sample sizes nE ∈ {100, 200, 400}, compare section 4.1.
While too few models make it easy to miss a truly good candidate (because the validation ranking might
be incorrect), too many models make it hard to identify a truly good candidate. When more test observa-
tions are available, a higher number of models can be evaluated before the test set ’overfitting’ occurs and
ÊFP(S) therefore decreases slower in S. For the numerical experiments presented in this work (section
4.1), we do not use (15) to determine S∗, as one would naturally do, but rather select the smallest S with
comparable ÊFP(S). By default, we define S∗ as the smallest S such that ÊFP(S∗) is still within one
standard error of max1≤S≤Smax ÊFP(S). This is indicated in figure 1. For nE = 200 the maximizer of
ÊFP(S) is S = 30 which yields ÊFP(30) = 82.51%. The simulation standard error associated to this
estimate is 0.17%. If we select the smallest S with comparable ÊFP(S) we obtain S∗ = 15, which gives
ÊFP(15) = 82.49%. Thus, the expected final performance is almost identical but choosing fewer models
will naturally result in a smaller adjustment for multiplicity and estimation bias in the evaluation study.
3.2 Study conclusion
Our framework provides a multiple test decision for the hypotheses system (2). After the evaluation study,
one might therefore partition the set of candidate models M = P ∪ N into positively and negatively
evaluated models P = {m ∈ S ⊂ M : ϕm = 1} and N = S \ P . In the case P = ∅, no performance
claim can be made and the evaluation study has failed in a strict confirmatory sense. When |P| = 1, only a
single model meets the requirements and the situation is clear. However, if |P| > 1, the investigator has the
choice which of the models m ∈ P should be implemented in practice.
When applying the maxT-approach, m∗ = argmaxm∈S Tm is a natural final model choice. In the co-
primary endpoint setting, this corresponds to m∗ = argmaxm∈S min(T Sem , T
Sp
m ), i.e. we select the model
for which the evidence that both endpoints are significant is maximal. It might however be reasonable to
select the final model according to other criteria. For instance, one may declare the final model to be
m∗ = argmaxm∈P(w · Ŝem + (1− w) · Ŝpm), w ∈ (0, 1).
This means we choose the final model such that a weighted average of empirical sensitivity and specificity
is maximized, given the null hypothesis was rejected. When w = 0.5 this corresponds to the maximization
of the (empirical) balanced accuracy (bAcc), or equivalently, the well known Youden-Index from all models
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Figure 1: Optimization of the expected final model performance EFP(S) as a function of the number
of models to be evaluated. The figure shows ÊFP(S) after 500 simulation runs for different evaluation
sample sizes nE = 100, 200, 400 for a single exemplary dataset from our simulation database. Besides the
maximum (+), the smallest S with comparable ÊFP(S) (within one standard error of the maximum) is
marked (×). For nE = 100, both points (+,×) coincide.
m ∈ P ⊂ S (Youden, 1950). Further criteria which are not directly tied to the discriminatory performance
such as model interpretability or calibration can of course also be considered.
4 Numerical experiments
4.1 Machine learning and evaluation
4.1.1 Setup
The goal of this first simulation study is to assess the properties of different model selection rules and our
statistical inference approach under realistic parameter settings in the machine learning context. To this end,
we investigate different methods on a large simulation database which was generated for related method-
ological comparisons (Westphal & Brannath, 2019b). While the overall binary classification accuracy was
our only performance measure of interest in earlier work, we turn to the investigation of sensitivity and
specificity as co-primary endpoints in the following. The simulation database consists of 144, 000 instances
of the complete machine learning pipeline. A single instance consists of training (T ), validation (V) and
evaluation (E) datasets which are all comprised of feature-label observations (x, y) sampled from the same
distribution D(X,Y ).
Different binary classification models were trained on the so-called learning data L = T ∪ V , compare
section 2.1. For that matter, we employed four popular learning algorithms (elastic net, classification trees,
support vector machines, extreme gradient boosting) with help of the R package caret (Kuhn & Johnson,
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2013; Kuhn et al., 2019). More concretely, we trained M = 200 initial candidate models, 50 models
obtained from randomly sampled hyperparameters per algorithm, on the training data T ⊂ L. The distinct
validation data V = L\T is then used for model selection. The models S ⊂M = {1, . . . ,M} selected for
the evaluation study are then re-trained on the complete learning data L = T ∪ V as this can be expected to
slightly increase their predictive performance. The selected models S ⊂M then undergo a final assessment
on the independent evaluation data E which is supposed to mimic a diagnostic accuracy study. The goal
of this final evaluation study is to estimate sensitivities and specificities of the selected models and to
obtain a test decision regarding hypotheses system (4). Ultimately, a final model m∗ ∈ S is selected to be
implemented in practice, if positively evaluated, compare section 3.2.
For each individual simulation instance, the distinct datasets L and E are sampled from the same joint prob-
ability distributions D(X,Y ). To generate the whole database, different distributions D(X,Y ) with varying
characteristics have been specified. The database consists of linear and non-linear tasks (ratio 1:2), indepen-
dent and dependent feature distributions (ratio 1:1) and different disease prevalences % ∈ {0.15, 0.3, 0.5}
(ratio 1:1:1). The learning data L is of size nL ∈ {400, 800} (ratio 1:1). The model selection was always
conducted on a hold-out validation dataset V ⊂ L of size nV = nL/4. Each learning dataset (including
the trained models) was used twice, once in connection with each of the considered evaluation dataset sizes
nE ∈ {400, 800} (ratio 1:1).
The true model performances θ = (Se,Sp) of all models are approximated with high precision on a large
population dataset (nP = 100, 000). This dataset was not used for any other purposes. The truly best model
is defined in line with the study goal outlined in section 2.2 as
m⊕ = argmaxm∈M ϑm = argmaxm∈Mmin(Sem,Spm +∆0). (16)
The parameter ∆0 is set to 0 for all experiments which expresses that we deem sensitivity and specificity to
be equally important. The corresponding maximal performance is denoted as ϑ⊕ = ϑm⊕ . The final model
m∗ ∈ S is chosen based on the evaluation data as m∗ = argmaxm∈S Tm, compare section 3.2. In case of
a tie, m∗ is chosen randomly from the set argmaxm∈S Tm. For a throughout description of the simulation
database we refer to Westphal and Brannath (2019b). R packages and scripts related to the simulation study
are publicly accessible.3
We initially divided the simulation database into two parts via a stratified random split with regard to the
above mentioned factors. In effect, all mentioned ratios are identical in both parts. The smaller subset
with 24, 000 instances was used in advance to perform a few methodological comparisons with the goal to
fine-tune certain aspects of the optimal EFP selection rule described in section 3.1. For instance, we altered
the way models are ranked initially and several details associated to numerical complexity of the algorithm
(number of iterations, convergence criterion), compare appendix B. The final algorithm was then fixed and
investigated on the main part which consists of 120, 000 instances, as described in the following.
4.1.2 Goals
Our overall goal is an assessment of important operating characteristics of the employed evaluation strate-
gies. An evaluation strategy is comprised of a selection rule (before evaluation) in and a statistical testing
procedure (for evaluation). The latter will always be conducted via the maxT-approach presented in section
2.4. When only a single model is selected, the maxT-approach reduces to the standard procedure for co-
primary endpoints, namely two independent (unadjusted) Z-tests for sensitivity and specificity which both
need to reject in order claim superiority.
3https://maxwestphal.github.io/SEPM.PUB/ (last accessed November 11, 2019)
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Figure 2: Distribution of ϑ⊕ and ∆⊕ stratified for disease prevalence % and learning sample size nL. Each
boxplot is based on 10,000 distinct points which amounts to 60,000 unique simulation instances in total.
The primary objective of this simulation study is therefore the comparison of different selection rules.
Hereby, we are mainly interested in the performance of our novel Bayesian approach designed to opti-
mize the expected final model performance (EFP), compare section 3.1. This approach is referred to as
optimal EFP selection rule. Its main competitor is the within 1 SE rule for which S is defined as all models
m ∈ M with preliminary balanced accuracy b̂Accm(V) = (Ŝe(V) + Ŝp(V))/2 (estimated on V) not more
than one standard error below the maximal b̂Accm(V). A similar rule has lead to vast improvements rela-
tive to the traditional default approach in previous work concerned with the overall accuracy (Westphal &
Brannath, 2019a, 2019b). The default rule selects the single best model in terms of b̂Acc(V) for evaluation
and will serve as a secondary comparator. Additionally, we consider the oracle selection rule which cannot
be implemented in practice but gives an insight on the theoretically achievable performance (of selection
rules). The oracle rule always selects the truly best model S = {m⊕} as defined in (16). To reduce the
computational complexity of the simulation study we hard-thresholded the number of evaluated models to
Smax =
√
nE . Performance ties are resolved by including all tied models for evaluation. In effect, the
default and oracle rule also occasionally select more than one model for evaluation.
Our main research hypothesis going into the simulation is that the optimal EFP improves the expected
final performance (EFP) and statistical power compared to the within 1 SE rule while having comparable
estimation bias. Moreover, we require that the FWER is still controlled at the desired level which is set to
α = 2.5% (one-sided) in all scenarios.
4.1.3 Results
Firstly, we investigate how well the feature-label relationships can be learned by the considered algorithms.
Figure 2 (left) shows the distribution of the truly best model performance ϑ⊕ over all unique 60, 000 learn-
ing instances. The results are stratified for disease prevalence % and learning sample size nL. We observe
that ϑ⊕ is increasing in both these factors, as expected. Overall, the median of ϑ⊕ lies between 79% and
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Figure 3: Probability of the event that the final model performance ϑm∗ = min(Sem∗ , Spm∗ +∆0) exceeds
a given threshold ϑ0 = ϑ⊕ − δ. ϑ⊕ is the true performance of the best candidate model. Each scenario
of learning and evaluation sample sizes (nL, nE) is based on 30000 repetitions of the complete machine
learning pipeline.
86% which we consider to be a very realistic range. Moreover, figure 2 (right) shows the distribution of
∆⊕ = Se⊕−Sp⊕ which indicates how balanced the accuracy of the best model is across the diseased and
healthy subpopulations. Note that for the oracle rule, the model selection is S = {m⊕} and thusm∗ = m⊕
is also the final model.
Figure 3 illustrates the true performance of the final selected model m∗ ∈ S whereby S depends on the
employed selection rule. Depending on the threshold value ϑ0 = Se0 = Sp0, figure 3 shows the (simulated)
probability P(ϑm∗ ≥ ϑ0 | δ) that the final chosen model has at least a performance of ϑ0 = ϑ⊕ − δ, δ > 0.
The general picture is that the optimal EFP and within 1 SE rules both clearly outperform the default rule.
Concerning our main comparison, we observe that the optimal EFP approach uniformly outperforms the
within 1 SE rule. The difference is however rather small, e.g. 0.791−0.735 = 0.056 (99% CI: 0.053-0.059)
at δ = 0.05 when averaging over all scenarios (nL, nE ). We also compared the mean expected performance
Eϑm∗ of both rules, which are 0.788 and 0.782, respectively. This comparison thus also shows a slight
advantage of the optimal EFP rule of an average performance gain of 0.007 (99% CI: 0.006-0.007). Further
details are provided in table 1 in appendix C.
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Figure 4: Rejection rate for the global null hypothesis (all prediction models have performance ϑm ≤ ϑ0 ) in
the evaluation study after models have been selected for evaluation by specified selection rule. δ = ϑ⊕−ϑ0
specifies if the global null is true (δ ≤ 0) or false (δ > 0). Each scenario of learning and evaluation sample
sizes (nL, nE) is based on 30000 repetitions of the complete machine learning pipeline. The significance
level is α = 2.5% (one -sided, dashed horizontal line).
Figure 4 shows the rejection rate rr(δ) = P(ϕm∗ = 1 | δ) as a function of δ = ϑ⊕ − ϑ0. The case δ = 0
or ϑ0 = ϑ⊕ corresponds to the smallest threshold value ϑ0 such that the global null hypothesis (none of
the initially trained models has a high enough performance) is true, compare (4). Thus, for δ ≤ 0 the
global null is true and the rejection rate rr(δ) should be bounded by α = 2.5% for all selection rules. Note
that this parametrization via δ is necessary as ϑ⊕ is not fixed over all simulation instances as illustrated in
figure 2. The results clearly show that FWER control is given for all rules in all scenarios. In appendix C,
table 1, we also show the FWER when the (pre-)selection process is not incorporated in the test decision.
More precisely, we are then looking at the type I error rate of the final statistical test for hypothesis system
(2) which is equal to P(ϕm∗ = 1 |ϑ0 = ϑm∗). We refer to this quantity as conditional FWER which is
necessarily larger than rr(0) but still controlled, i.e. smaller than α in all cases. Note that strictly speaking
it is only an upper bound of the proper conditional FWER P(ϕm∗ = 1 |ϑ0 = maxm∈S ϑm) which was not
’recorded’ in our simulation database.
In the situation δ > 0, the threshold value ϑ0 is small enough such that the global null is no longer true,
i.e. there is at least one model m ∈ M with true performance ϑm > ϑ0 which we seek to detect. Larger
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rejection rates are thus positive as they correspond to statistical power. Concerning power, the ranking of
selection rules is the same as in the expected final performance comparison (figure 3). The multiple testing
approaches optimal EFP and within 1 SE outperform the default rule clearly. The power increase is up to
30%, depending on the scenario and δ. The power difference between optimal EFP and within 1 SE rule is
always positive but only noteworthy in the case nE = 800.
Table 1 in appendix C shows further comparisons of the investigated selection rules. For instance, the
properties of the corrected point estimators θ˜m∗ = (S˜em∗ , S˜pm∗) are assessed, compare 2.4. When only a
single model is evaluated, θ˜ corresponds to θˆ, the raw (slightly regularized) point estimate, compare section
2.3. For example, the combined mean absolute deviation
MAE2 = E(|S˜em∗ − Sem∗ |+ |S˜pm∗ − Spm∗ |)/2
is decreased when multiple models are evaluated simultaneously (optimal EFP: 0.042; within 1 SE: 0.049,
averaged over both cases nE ∈ {400, 800}) compared to the default rule rule (0.074). This might seem
counterintuitive at first, but is in line with previous findings (Westphal & Brannath, 2019b). This observation
can be explained with the on average increased final model performance ϑm∗ = min(Sem∗ ,Spm∗) which
results in a decreased variance of the binomially distributed estimators. In contrast, the estimation bias is
more pronounced when multiple models are evaluated. Note that the bias E(ϑ˜m∗ − ϑm∗) is negative (by
construction) as we use the corrected estimator ϑ˜m∗ = min(S˜em∗ , S˜pm∗), compare section 2.4. Finally,
we note that the optimal EFP rule on average selects roughly two to three fewer models for evaluation
compared to the within 1 SE rule, compare table 1 in appendix C.
4.2 Least favorable parameter configurations
In the previous section, the operating characteristics of our simultaneous inference framework were assessed
in a variety of realistic scenarios in the predictive modeling context. In contrast, we investigate the worst
case type I error rate of the maxT-approach for different sample sizes in the following. For that matter, we
simulate synthetic data under least favorable parameter configurations (LFCs) as described in 2.4 and also
close to LFCs.
We assume that S ∈ {1, 10, 20} models are assessed on the evaluation data and consider the case when Se0
and Sp0 are identical. For each simulation run, we randomly draw a binary vector b such that |b| = S/2.
When S = 1, we set b = (1). The true parameters Se and Sp are defined as
Seb,m = bm(Se0−(m− 1)) + (1− bm),
Spb,m = bm + (1− bm)(Sp0−(S −m)).
Hereby, the parameter  ∈ {0, 0.001, 0.002} expresses how close we are to a true LFC which corresponds to
 = 0. For instance, for S = 10, Se0 = Sp0 = 0.8,  = 0.001, a possible (nearly least favorable) parameter
configuration is given by
b = (1 , 1 , 0 , 1 , 0 , 0 , 0 , 1 , 1 , 0 ), (17)
Seb,m = (0.800, 0.799, 1 , 0.797, 1 , 1 , 1 , 0.793, 0.792, 1 ),
Spb,m = (1 , 1 , 0.793, 1 , 0.795, 0.796, 0.797, 1 , 1 , 0.800).
If  were 0 instead of 0.001 in (17), all elements in Seb, and Spb, different from 1 would change to Se0 =
Sp0 = 0.8 (assuming the same b). We mainly consider a (fixed) disease prevalence of % = 0.2. Hence,
there are n1 = %n diseased and n0 = n − n1 subjects, whereby n ∈ {200, 400, 800, 4000, 20000} in our
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Figure 5: Family-wise error rate (FWER) in dependence of the total sample size n = n1 + n0 (logarithmic
scale) under different parameter configuration (specified by ϑ0, ) and disease prevalences % = n1/n. In all
cases, S/2 (randomly selected) models have Sem = Se0 and Spm = 1 and vice versa for the remaining
S/2 models. For S = 1, Se = Se0 and Sp = 1. The target significance level is α = 2.5% (one-sided).
Nsim = 10, 000.
simulation. Additionally, the scenarios with  = 0 were also repeated with a balanced class distribution (% =
0.5). In all simulations, the true correlation between all estimators which belong to non-trivial variables
(true mean not equal to one), e.g. Ŝe1 and Ŝe2 in the example (17), is set to 0.5. Results from a sensitivity
analysis regarding this specification are reported at the end of this section. Any empirical sensitivity is of
course independent from any empirical specificity. Data generation, i.e. sampling of the similarity matrices
QSe and QSp (section 2.3) based on the above specifications, was conducted with help of the bindata
package in R (Leisch, Weingessel, & Hornik, 1998, 2012). The number of simulation runs was set to
Nsim = 10, 000 which results in a (point-wise) upper bound for the standard error of the simulated FWER
of 0.5/
√
10.000 = 0.005.
Figure 5 shows the simulation results stratified by all relevant factors. In all scenarios, the results match the
theoretical findings from section 2.4 in that the asymptotic FWER under LFCs converges to α = 0.025 as a
function of the sample size n. When the disease prevalence is increased from % = 0.2 to 0.5, the FWER is
(slightly) decreased. In comparison, the number of models S and the parameter  have a stronger influence
on the FWER. In the most extreme case, the FWER is close to 14% for S = 20 and Se0 = Sp0 = 0.9 for
n = 200 and reaches its target α = 0.025 not before n = 20000. Remember that there are only n1 = %n
diseased subjects, so the ’relevant’ sample size is much smaller, particularly in the case % = 0.2. When
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we relax the least favorable parameter configurations ( = 0) to only slightly worse model performances
( = 0.001) such as in (17), the FWER declines much faster in n. For Se0 = Sp0 = 0.8 the target
significance level is met already at around n = 400 ≈ exp(6) total or n1 = 80 diseased observations.
For Se0 = Sp0 = 0.9, this number more than doubles to roughly n = 1100 ≈ exp(7) for S = 10 and
n = 1800 ≈ exp(7.5) for S = 20.
In an ancillary simulation (Nsim = 5000), we also investigated results under different true correlation
structures of the estimators Ŝe, Ŝp (independence, equicorrelation, autocorrelation) and strengths. None of
these changes resulted in qualitatively different results than those shown in figure 5. Additionally, we also
investigated the cases Se0 = 0.8 and Sp0 = 0.9 and vice versa in the LFC scenario (Nsim = 5000). Hereby,
it became apparent that the FWER development depends almost solely on the sensitivity value(s), at least in
the low prevalence case (% = 0.2). This can be explained due to the lower number of diseased subjects, and
hence lower ’relevant’ sample size. When % = 0.5, the problem becomes symmetric and the FWER curves
for θ0 = (0.8, 0.9) and θ0 = (0.9, 0.8) are thus not distinguishable and lie in between those shown in figure
5, i.e. between the cases θ0 = (0.8, 0.8) and θ0 = (0.9, 0.9).
The worst-case projection of parameter values to one, e.g. of Sp1,Sp2,Se3, . . . in (17), is not really realistic.
For instance, in the case Sem = 0.9 Spm = 1 and % = 0.2, the overall accuracy is Accm = 0.98. In real-
world problems, such a high accuracy is rarely attainable. We therefore also considered an alternative data-
generating scenario where (17) is modified such that the overall accuracy for each model m is bounded by
0.95. This change decreased the FWER across almost all scenarios by roughly 0.5 to 2 percent. Otherwise,
the results from this sensitivity analysis do not deviate noticeably from those shown in figure 5.
5 Discussion
5.1 Summary
In this work we have investigated statistical and study design related methods to improve diagnostic accu-
racy studies with co-primary endpoints sensitivity and specificity. The main idea is to allow that multiple
candidate models are assessed simultaneously on the evaluation data, thereby increasing the likelihood of
identifying one that performs sufficiently well. In modern medical testing applications this is necessary
because often hundreds or thousands of model architectures and preprocessing pipelines are compared on
preliminary data, making a final decision before the evaluation study difficult and prone to error. Our ap-
proach allows to wait for the test data until a final decision is made and thereby possibly correcting an
erroneous model ranking.
The main advantages of the multiple testing approach are the on average increased final model performance
and the vastly improved statistical power. As multiple comparisons are now conducted on the final dataset,
inferences need to be adjusted via a multiple testing procedure. For that matter, we employed a variation
of the so-called maxT-approach which is based on a multivariate normal approximation (Hothorn et al.,
2008). This framework also enables a corrected, conservative (point) estimation but the unbiasedness of
the default single model evaluation strategy is lost. An important question of practical interest is how
models should be selected for evaluation. Besides the heuristic within 1 SE rule, we also employed the
novel optimal EFP rule. This Bayesian approach aims to optimize the expected final model performance
(EFP) before the evaluation study. Given the model assumptions and involved numerical approximations,
it provides is with an approximate Bayes action for the considered subset selection problem as it optimizes
the posterior expected utility, i.e. the EFP. The underlying model for that matter is based on the hold-out
validation data from the model development phase which is readily available before the evaluation study.
20
WESTPHAL ET AL. (2019)
The comparison regarding all important criteria (performance, power, estimation bias) turns out in favor for
the more elaborate optimal EFP approach. However, the advantage relative to the within 1 SE rule was small
to moderate in most scenarios. For instance, the average performance increase in terms of ϑ = min(Se, Sp)
was around between 0.7% in the main simulation study (section 4.1). We conclude that the optimal EFP
rule yields a vast improvement over the default approach but the conceptually and implementation wise
simpler within 1 SE rule yields almost as good of results.
As was laid out in section 3.1, an advantage of the optimal EFP selection rule is that the it does not involve
any tuning parameter, in contrast to other potential decision theoretic approaches and the within k SE rule
(k > 0). Another major advantage is that the optimal EFP rule takes into account the evaluation sample
size, i.e. it selects more models when more data is (expected to be) available the evaluation study. This
is not the case for the simpler within 1 SE rule which only takes into account estimation uncertainty in
the validation stage, before the evaluation study. Moreover, we can adapt key characteristics if we know or
expect that the learning data is not representative for the evaluation study ahead. This is for instance the case
if our preliminary data is from a case-control study with non-representative class balance. As the disease
prevalence is a dedicated parameter of our optimal EFP algorithm (appendix B), we can easily change it
to another fixed value or specify a prior distribution. We have not investigated this possible adaptivity in
simulations so far. A disadvantage of the optimal EFP rule is the increased mathematical and numerical
complexity.
5.2 Limitations
Our simultaneous test procedure guarantees asymptotic strong control of the Family-wise error rate. As
illustrated in section 4.2, the finite sample performance under least favorable parameter settings can be
unsatisfactory, depending on the exact scenario. As expected, the FWER depends primarily on the threshold
values Se0 and Sp0 because the employed normal approximation performs worse near the boundary of the
unit interval. Control of the FWER is also worse when the number of models S is large or when the disease
prevalence is low.
We could aim to improve this limitation, e.g. by not utilizing the correlation structure between models
which would result in a larger critical value and thus stricter inference. However, as indicated in the main
simulation (section 4.1), the average FWER under realistic conditions is far below the significance level,
compare figure 3 and table 1. Note that in contrast to the simulation study presented in section 4.2, the
analysis in section 4.1 is an average risk assessment. The average is taken with respect to different gen-
erative distributions over the relevant parameter values, i.e. model performances θ = (Se,Sp) and their
dependency structure. These generative distributions are not known but rather implicit in the sense that
the relevant parameters dependent on the (feature-label) data generating distribution(s) DX,Y (which are
known) and properties of the learning algorithms. Their resulting characteristics are partially described
in figure 2 and deemed to be realistic for real-world prediction tasks. Note that the results from section
4.1 can be generalized to other prediction tasks and learning algorithms which result in similar generative
distribution over parameters θ (and dependency structure thereof).
Together, the results from both simulation studies, realistic scenarios in section 4.1 and the worst-case
assessment in section 4.2, indicate that parameter configurations in reality are rarely least favorable. An
associated observation was made at the end of section 4.2. When the LFC is made only slightly less
unfavorable, the FWER declines faster in n. In the machine learning context, it would be reasonable to
assume that the larger the number of models S, the less likely least favorable parameters become. After all,
the LFC corresponds to the setting that fromM initial candidate models, S have the exact same performance
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at the boundary of the null hypothesis and are all selected for evaluation. While this reasoning does apply
to the practitioner, it does not apply from a purely frequentist viewpoint as probability statements over true
parameters are irrelevant when (worst-case) FWER control in the strong sense is the goal.
While the multiple testing approaches certainly increase the flexibility in the evaluation study, prediction
models still need to be fixed entirely before the study. Verifying this could pose challenges in a regulatory
context as merely specifying the learning algorithm and hyperparameters would not be enough in this regard.
As the exact resulting models, i.e. their weights, often depend also on the random initialization in the
training process, only a full specification of model architecture and weights can be considered sufficient in
that regard. Another practical issue is related to the assessment of multiple assisted medical testing systems.
Unlike automated disease diagnosis, which is the main target of our methods, a (final) human decision is
needed for each prediction in this case. For the evaluation study this would imply, in the worst case, that an
equal number of independent readers is needed to supply such a decision. This aspect thus puts a natural
(resource) limit on the number of evaluated models and needs to be considered in the planning stage.
5.3 Extensions
Our framework can be extended to classification problems with more than two classes, e.g. different dis-
ease types or severity grades. More generally, it can be employed in arbitrary prediction tasks for which
not only the overall performance is important but also the performance in different subpopulations. So far,
we have not considered such problems in simulation studies. It can however be expected that the operating
characteristics of our multiple testing framework will largely depend on the sample size of the smallest sub-
population. This could render the approach practically infeasible for problems with many or an unbalanced
distribution of subclasses.
A rather simple adaptation which might be considered in the future is hypotheses weighting. The employed
maxT-approach can rather easily be adopted for that matter (Dickhaus & Gierl, 2012). That is to say, rather
then splitting up the significance level α equally for each of the S hypotheses, one could spend more on the
most promising models. A natural source of information to determine the α ratio is of course the empirical
data from the model development phase. Further research on an optimal weighting and its impact on e.g.
statistical power is however necessary.
A step further in connecting the evidence before and after the evaluation study would demand Bayesian
methods. In a Bayesian model, a prior distribution could be based on validation results and be updated
through the evaluation data. We have already experimentally employed a recently proposed multivariate
Beta-binomial model for that matter (Westphal, 2019). While this approach works reasonably well in real-
istic scenarios, several challenges remain. A main difficulty here is to specify an ’honest’ prior distribution,
i.e. to not have an arbitrarily optimistic prior. The contrary can however happen in practice when the prior
is based on the validation data without any adjustments, in particular when the number of initial candidate
models M is large. A correction strategy which accounts for the selection process before the evaluation
study should thus be developed to avoid such overoptimism.
Our optimal EFP subset selection algorithm is designed to maximize the expected final model performance.
While this is a natural goal, there are many other potential utility functions that could reasonably be opti-
mized before the evaluation study. In particular, utility functions based on statistical power, estimation
bias or a weighted combination of different criteria appear reasonable. Our novel approach (section 3.1,
appendix B) could also be used here to make the specification of the utility function independent of the
subset size and thereby simpler for the practitioner. In its current form, our implementation uses several
approximations and can potentially be improved regarding its numerical efficiency.
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A Technical details
A.1 Parameter estimation
In the following, we briefly summarize the multivariate Beta-binomial model introduced by Westphal (2019)
and how it can be used to obtain the regularized point estimators introduced in section 2.3. We apply
the procedure independently for diseased (Se) and healthy (Sp) subsample but keep the notation in the
following generic (ϑ) to streamline the presentation. We assume that n observations of S binary random
variables Qim, i = 1, . . . , n, m ∈ S = {1, . . . , S}, are available. In the context of this work Qim =
1(fˆi(Xi) = Yi) indicates a correct prediction of model m on the i-th observation. We suppose independent
observations (Qi1m and Qi2m) but two variables Qim1 and Qim2 , m1,m2 ∈ S, may be correlated. This
entitles us to assume i.i.d. observations Qi = (Qi1, . . . , QiS) from a multivariate Bernoulli distribution.
We are interested in the joint distribution of Q = (Q1, . . . , QS), in particular in the marginal means ϑm =
P(Qm = 1). This may be modeled extensively by a multinomial distribution with parameter vector p ∈
P = {(0, 1)2S : |p|1 = 1} of length 2S . Hereby pq = P(Q = q) is the probability to observe the
event q ∈ {0, 1}S . The marginal mean ϑm can than be derived as the sum of all relevant probabilities, i.e.
ϑm =
∑
q: qm=1
pq.
A popular Bayesian model that incorporates the multinomial likelihood is the so-called Dirichlet-
multinomial model. Hereby, a Dirichlet prior for p with concentration parameter γ ∈ R2S+ is assumed.
According to Westphal (2019), a multivariate Beta distribution can be derived as a simple linear transforma-
tion of a Dirichlet distribution and can thus be employed for the situation at hand. However, this extensive
approach is often infeasible in practice due to large number of parameters. Besides the full 2S-dimensional
parametrization, a reduced representation can be derived which consists of a prior sample size ν ∈ R+ and
a (symmetric) prior moment matrix A ∈ RS×S+ . This amounts to a Beta(Amm, ν −Amm) prior for ϑm =
P(Qm = 1) and a Beta(Am1m2 , ν −Am1m2) prior for the probability ϑm1m2 = P(Qm1 = 1 ∧Qm2 = 1).
The prior distribution pi(ϑ) ≡ mBeta(ν,A) can easily be updated via the observed data (n, U ) whereby n
is the sample size and the update matrixU = U(Q) consists of elementsUm1m2 which denote the observed
absolute frequencies
∑n
i=1 1( Qim1 = 1 ∧ Qim2 = 1). The posterior distribution of ϑ given the observed
data is then pi(ϑ |Q) ≡ mBeta(ν?,A?) with ν? = ν+n andA? = A+U . This simple update rule is sim-
ilar to the univariate Beta-binomial model and can be derived from the well-studied Dirichlet-multinomial
model (Westphal, 2019).
We can employ the mBeta-binomial model to replace our usual estimators
ϑˆ = u/n and Σˆ = (nU − uu>)/n3
for ϑ and Σ = cov(ϑˆ) whereby u = diag(U). We will replace the estimators in the last equation by the
mean and covariance of the posterior distribution pi(ϑ |Q) which are given by
ϑˇ = Eϑ = α?/ν? and Σˇ = cov(ϑ) = (A? −α?(α?)>)/((ν?)2(ν? + 1))
whereby α? = diag(A?) (Westphal, 2019). If we employ a vague prior distribution which is composed of
S independent uniform distributions this implies ν = 2 and all elements of A are equal to 0.5, except the
diagonal which consists of ones. This amounts to adding two pseudo observations (one success, one failure)
for each margin whereby half of the success pseudo-observation is counted as common for all variable pairs.
Marginally, this approach thus has the same effect as using the popular univariate Beta-binomial posterior
mean Eϑm = (um + 1)/(n+ 2) as a point estimator ϑˇm (assuming a uniform prior), compare Bolstad and
Curran (2016, Chapter 9).
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We have applied the estimators ϑˇ and Σˇ independently for sensitivity and specificity in all numerical ex-
periments in this work. Note that the difference between the usual (ϑˆ, Σˆ) and regularized estimators (ϑˇ, Σˇ)
vanishes asymptotically. In effect, the asymptotic results in section 2.4 apply regardless of which estimators
are used. For finite sample sizes the procedure has the advantage to prohibit zero variance estimates, as
described in section 2.4. Note that, strictly speaking, the notation mBeta(ν,A) does only define first an
(mixed) second-order moments of the distribution and is not a complete characterization. This is however
sufficient for our purposes as a multivariate normal approximation is used for the statistical inference which
only depends on this information. Note that we also use the mBeta-binomial model for our optimal EFP
selection rule, compare section 3.1. Here it is rather used to construct a generative mBeta distribution from
the validation data (via the update rule mentioned above). This generative distribution then builds the foun-
dation to simulate the evaluation study to determine the optimal number of models to evaluate prior to the
study, compare also appendix B.
A.2 Statistical inference
In this section, we re-state and prove the theoretical results from section 2.4. In the following, we work with
two samples, i.e. n1 diseased and n0 healthy subjects. Hereby, we need to assume that n1/n → % 6= 0 as
n = n1 + n0 →∞. We can then derive min(n1, n0)→∞ from n→∞. This is for instance given under
simple random sampling with a fixed disease prevalence, i.e. when assuming n1 ∼ Bin(n, %), n0 = n−n1,
% ∈ (0, 1).
Theorem 1 Assume Sem−Se0 6= Spm−Sp0 for all m ∈ S. Then, under the LFC θb = (Seb,Spb),
T b(n)
D−→ NS(0,Rb), n→∞,
whereby T b = T b(n) is defined in (7) andR
b = BRSeB + (IS −B)RSp(IS −B).
PROOF Under the LFC θb, the sub-vector T Seb of elements of T
Se indicated by bm = 1 converges in
distribution to a multivariate normal random variable of dimension |b| = ∑Sm=1 bm due to the multivariate
central limit theorem. Similarly, the sub-vector T Spb of elements of T
Sp indicated by bm = 0 converges to
a multivariate standard normal of dimension S − |b|. We write
T Seb
D−→ ZSeb ∼ N|b|(0,RSeb ) and T Spb
D−→ ZSpb ∼ N(S−|b|)(0,RSpb ), n→∞.
We denote the full, S-dimensional versions of these limiting distributions by ZSe ∼ NS(∆Se,RSe) and
ZSp ∼ NS(∆Sp,RSp). ZSe and ZSp are singular because they are constant in the remaining, not directly
relevant entries.
The random variables T Se and T Sp are independent of each other because they are based on distinct samples.
This also holds for their limitsZSe andZSp. Moreover, left multiplication with the matrix (B2)> (compare
2.4) defines a linear and thus continuous mapping. Together with the continuous mapping theorem, this
implies
T b(n) = (B2)
>T2(n)
D−→ (B2)>Z2 = Zb, n→∞
whereby Z2 ∼ N2S(∆2,R2) with
∆2 = (∆
Se,∆Sp) and R2 =
(
RSe 0
0 RSp
)
.
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The matrix (B2)> is fixed and the distribution of Zb is thus NS(0,Rb) with
Rb = (B2)R2(B2)
> = BRSeB + (IS −B)RSp(IS −B) ∈ [−1, 1]S×S .
Note thatB and (IS −B) are diagonal and thus symmetric matrices. This concludes the proof. 
Lemma 1 Assume Sem−Se0 6= Spm−Sp0 for all m ∈ S. Then
Rˆb = BˆRˆSeBˆ + (IS − Bˆ)RˆSp(IS − Bˆ)
is a consistent estimator forRb.
PROOF The sample correlation matrix RˆSe derived from the sample covariance matrix ΣˆSe is a consistent
estimator for RSe, the same holds for RˆSe. Moreover, bˆ converges in probability against b. An analogue
statement thus holds for Bˆ. These individual convergences can be connected with help of the continuous
mapping theorem to derive the result. 
Proposition 1 With cα calculated according to (11), the simultaneous testing procedure ϕ defined by
ϕm = 1 ⇐⇒ Tm = min(T Sem , T Spm ) > cα,
defines a multiple test with asymptotic strong FWER control at level α for hypothesis system (2).
PROOF We replace ϕm in the assertion with ϕbm defined by
ϕbm = 1 ⇐⇒ T bm > cα
with T b defined in (7). Then the modified assertion holds due to theorem 1, lemma 1 and the results
of Hothorn et al. (2008). As T b is unknown (as b is unknown) in practice, we need to replace T b with
T ≤ T b which will result in equal or less rejections. This proves the original statement.
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B Optimal subset selection
The optimal EFP model selection rule was described in section 3.1. In this section, the numerical imple-
mentation is described in more detail in algorithm 1. The input parameters are described in the following,
including their default values in the simulation study described in section 4.1.
• ∆0 = Se0−Sp0 indicates the relative importance of sensitivity and specificity. In the numerical
experiments in this work, we have only considered the case ∆0 = 0.
• QV = (QSeV ,QSpV ) are the validation similarity matrices, compare section 2.3.
• Smax is the maximum number of models to be evaluated. By default, we set Smax = √nE . The
main purpose of this threshold is to reduce the computational complexity of the optimization pro-
cess in our simulation study.
• prerank = function(QV, Smax). The initial list of candidate models is ranked initially to
reduce the subset selection problem S ⊂M to the selection of the optimal number S ∈ {1, . . . ,M}
of models to be evaluated. By default, the ranking is conducted according to min(T Se(V), T Sp(V))
whereby the test statistics are calculated similar to (5) but based on the validation data V .
• moment_matrix = function(Q) converts the similarity matrixQ into the first and second order
moment matrix U which was described in appendix A.1.
• νp = (νSep , νSpp ) andAp = (ASep ,ASep ) are initial prior parameters. We employ simple independent
uniform priors per default which correspond to νp = 2 and Ap is a S × S-matrix with all entries
equal to 0.5 except diagonal entries which are equal to 1. This amounts to letting the generative
prior distribution being completely determined by the hold-out validation data.
• max.iter is the maximum number of iterations, set to 250 by default. This number was mainly
chosen for our simulation study. For a single run of the algorithm for a real use-case, a larger
number of iterations (500 to 1000) is easily feasible and hence recommended.
• num.tol is the numerical tolerance for the stopping criterion, set to 0.001 by default.
• n is the (assumed) sample size for the evaluation study. We assume simple random sampling.
Hereby we assume a Beta prior for the disease prevalence % = P(Y = 1) which is constructed from
the learning data. That is, we first sample % ∼ Beta(1 + nL1 , 1 + nL0 ) and then n1 ∼ Bin(n, %) and
finally set n0 = n− n1. Of course, in practice this could easily be adapted when more information
on % is available. This is in particular useful (and recommended) when the learning data is from a
case-control study with non-representative disease prevalence.
• mstar = function(θˆ, ...) is a function of the evaluation data, i.e. of θˆ = (Se,Sp) the empir-
ical test performances and potentially further parameters (e.g. ŝe(Se)). By default, the final model
is chosen as m∗ = argmaxm∈S min(T Sem , T
Sp
m ).
• Sstar = function(E, ...) is a function of the simulation result matrix E. By default, we
choose S∗ as the smallest S such that ÊFP(S∗) is not more than one standard error smaller than
maxm∈S ÊFP(S) in the current iteration. This is illustrated at the end of section 3.1 in figure 1.
• sample = function(dist, N, ...) returns a sample of the input probability distribution (first
argument) of size N (second argument). Samples from the mBeta distribution are obtained via a
copula approach (Westphal, 2019).
• pmin(u,v) = (min(um, vm))m=1,...,M is the pairwise minimum of two vectors u,v of length M .
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Algorithm 1: Pseudo code algorithm for the optimal EFP model selection rule: Optimization of the ex-
pected final model performance depending on the (number of) models to be evaluated.
Input: QV , Smax, ∆0, n, νp,Ap, max.iter, num.tol
Result: S∗ = 1
# rank models and reduce number of models to Smax
QV = prerank(QV, Smax);
# construct posterior (= generative prior) distribution pi based on prior (νp,Ap) and validation dataQV
νSe = νSep + nrow(Q
Se);ASe = ASep + momemt_matrix(Q
Se); piSe = mBeta(νSe,ASe);
νSp = νSpp + nrow(QSp);ASp = A
Sp
p + momemt_matrix(QSp); piSp = mBeta(νSp,ASp);
pi = (piSe, piSp);
# initialize evaluation study result matrix E and ÊFP
E = matrix(NA, nrow=max.iter, ncol=Smax); ÊFP =rep(NA,Smax);
i = 1;  =∞;
# each iteration of the while loop represents a single simulated evaluation study
while i ≤ max.iter &  > num.tol do
# sample true parameters ϑ = (Se,Sp) including correlation structure C = (CSe,CSp) from prior pi
(Se,CSe) = sample(piSe, N = 1); (Sp,CSp) = sample(piSp, N = 1); ϑ = pmin(Se,Sp + ∆0);
# determine sample sizes n1 and n0
% = sample(Beta(1 + nL1 , 1 + nL0 ), N = 1);
n1 = sample(Bin(n, %), N = 1); n0 = n− n1;
# construct sampling distribution of estimators Ŝe, Ŝp based on these parameters
pSe = mBin(Se,CSe, n1); pSp = mBin(Sp,CSp, n0);
# sample parameter estimates (’the observed data’) ϑˆ from p = (pSe, pSp)
Ŝe = sample(pSe, N = 1)/n1; Ŝp = sample(pSp, N = 1)/n0; ϑˆ = (Ŝe, Ŝp);
for S=1 to Smax do
# determine empirically best model given S where evaluated
m∗ = mstar(θˆ[1:S], ...);
# determine and save true performance of model m∗
E[i, S] = ϑ[m∗];
end
# estimate EFP by averaging over all simulated evaluation study results so far
ÊFP = colMeans(E, na.rm=T);
# determine optimal number of models
S∗ = Sstar(ÊFP, ...);
 = sqrt(var(E[ ,m∗], na.rm=T)/i); i = i+ 1;
end
C Additional simulation results
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Table 1: Detailed comparison of subset selection rules, stratified for evaluation sample size nE ∈ {400, 800},
compare section 4.1. All cells show expectations or probabilities, each estimated based on Nsim = 60000
simulation instances. The last column displays mean differences between the optimal EFP and within 1 SE
rules including unadjusted 99% confidence intervals.
nE oracle default within 1 SE optimal EFP optimal EFP - within 1 SE
Eϑ∗ 400 0.819 0.754 0.789 0.794 0.005 ( 0.005, 0.006)
800 0.819 0.754 0.793 0.800 0.007 ( 0.007, 0.008)
P(ϑ∗ > 0.75) 400 0.980 0.569 0.781 0.834 0.053 ( 0.049, 0.057)
800 0.980 0.572 0.813 0.876 0.063 ( 0.060, 0.067)
rr(0.10) 400 0.743 0.386 0.578 0.609 0.030 ( 0.026, 0.034)
800 0.916 0.507 0.773 0.832 0.059 ( 0.056, 0.063)
rr(0.05) 400 0.236 0.085 0.105 0.111 0.007 ( 0.004, 0.009)
800 0.514 0.180 0.280 0.301 0.021 ( 0.017, 0.024)
rr(0.00) 400 0.004 0.001 0.001 0.001 0.000 (-0.000, 0.001)
800 0.007 0.001 0.001 0.001 -0.000 (-0.000, 0.000)
FWER 400 0.004 0.017 0.011 0.011 -0.000 (-0.002, 0.001)
800 0.007 0.019 0.010 0.009 -0.002 (-0.002, -0.001)
Bias 400 -0.015 -0.009 -0.022 -0.022 0.000 (-0.000, 0.000)
800 -0.009 -0.005 -0.016 -0.017 -0.001 (-0.001, -0.001)
MAE2 400 0.034 0.076 0.053 0.046 -0.006 (-0.007, -0.006)
800 0.026 0.071 0.044 0.037 -0.008 (-0.008, -0.007)
P(O1) 400 0.536 0.603 0.492 0.490 -0.001 (-0.006, 0.004)
800 0.574 0.623 0.512 0.498 -0.013 (-0.018, -0.008)
P(O2) 400 0.344 0.192 0.098 0.114 0.016 ( 0.013, 0.019)
800 0.338 0.189 0.093 0.093 0.000 (-0.003, 0.003)
ES 400 1.332 1.726 13.269 9.808 -3.461 (-3.531, -3.392)
800 1.332 1.732 15.298 13.615 -1.683 (-1.775, -1.592)
Performance:
Eϑ∗ = Emin(Se∗,Sp∗) (expected true performance ϑ∗ of final selected model)
P(ϑ∗ > 0.75) (probability to obtain a final model with performance ϑ∗ > 0.75)
Test decisions:
rr(0.10) = P(ϕ∗ = 1 | δ = 0.10) (power, δ = ϑ⊕ − ϑ0 is the difference between
truly highest performance ϑ⊕ and threshold ϑ0)
rr(0.05) = P(ϕ∗ = 1 | δ = 0.05) (power)
rr(0.00) = P(ϕ∗ = 1 | δ = 0.00) (unconditional FWER, i.e. for hypothesis system (4))
FWER = P(ϕ∗ = 1 |ϑ0 = ϑ∗) (conditional FWER, i.e. for hypothesis system (2))
Estimation:
Bias = E(ϑ˜∗ − ϑ∗) (bias regarding estimation of ϑ∗ = min(Se∗,Sp∗))
MAE2 = E(|S˜e∗ − Se∗|+ |S˜p∗ − Sp∗|)/2 (combined mean absolute error of corrected point estimates
S˜e∗ and S˜p∗ for parameters Se∗, Sp∗ of final selected model)
P(O1) = P(S˜e∗ > Se∗ ∨ S˜p∗ > Sp∗) (probability to overestimate Se∗ or Sp∗)
P(O2) = P(S˜e∗ > Se∗ ∧ S˜p∗ > Sp∗) (probability to overestimate Se∗ and Sp∗)
Other:
ES (expected number of models selected for evaluation study)
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